MedTrace Logo

Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

NCT05652855 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-01-09

No results posted yet for this study

Summary

This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in participants with advanced or metastatic solid tumors.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

MHB088C for Injection

MHB088C for Injection, an antibody drug-conjugated molecule (ADC)

Sponsors & Collaborators

  • Minghui Pharmaceutical Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2026-01-31
Completion
2026-07-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652855 on ClinicalTrials.gov